EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection

Connor T Murphy, Grace L Williamson, Luis Ontiveros-Padilla, Aaron T Hendricksen, Brandi T Johnson-Weaver, Hae Woong Choi, David M Gooden, Santhosh Kalpathy, Alexandra M Lopez, Erik S Pena, Jacob M Bachelder, Rani S Sellers und 3 weitere

RSC Pharmaceutics · 2026 · 3 (4) · 1022-1033

DOI: 10.1039/d5pm00380f ↗

Kurz gefasst

Fachartikel in der Zeitschrift RSC Pharmaceutics, 2026. Verfasst von Connor T Murphy und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, UNC Chapel Hill NC USA ainsliek@email.unc.edu. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NCI NIH HHS, NIAID NIH HHS, NIH HHS.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A novel, mast cell activating small molecule was combined with the FDA-approved adjuvant, CpG, to produce an effective dual-adjuvanted mucosal vaccine formulation for orthopoxviruses.

Autor:innen und Institutionen

  • Division of Pharmacoengineering & Molecular Pharmaceutics, Eshelman School of Pharmacy, UNC Chapel Hill NC USA ainsliek@email.unc.edu.
  • Department of Pathology, Duke University Durham NC USA.
  • Department of Chemistry, Duke University Durham NC USA.
  • Department of Biomedical Engineering, NC State/UNC Chapel Hill NC USA.
  • Carborro High School Chapel Hill NC USA.
  • Department of Pathology & Laboratory Medicine, School of Medicine, UNC Chapel Hill NC USA.

ORCID-Profile: Kristy M Ainslie

Förderung

  • NCI NIH HHS
  • NIAID NIH HHS
  • NIH HHS
  • National Institutes of Health
  • National Cancer Institute
  • National Science Foundation
  • Division of Microbiology and Infectious Diseases

Zitieren

APA

Murphy, C. T., Williamson, G. L., Ontiveros-Padilla, L., Hendricksen, A. T., Johnson-Weaver, B. T., Choi, H. W., Gooden, D. M., Kalpathy, S., Lopez, A. M., Pena, E. S., Bachelder, J. M., Sellers, R. S., Abraham, S. N., Staats, H. F., & Ainslie, K. M. (2026). Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection. RSC Pharmaceutics, 3(4), 1022-1033. https://doi.org/10.1039/d5pm00380f

Vancouver

Murphy CT, Williamson GL, Ontiveros-Padilla L, Hendricksen AT, Johnson-Weaver BT, Choi HW, et al. Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection. RSC Pharmaceutics. 2026;3(4):1022-1033. doi:10.1039/d5pm00380f

BibTeX
@article{Murphy2026,
  author = {Murphy, Connor T and Williamson, Grace L and Ontiveros-Padilla, Luis and Hendricksen, Aaron T and Johnson-Weaver, Brandi T and Choi, Hae Woong and Gooden, David M and Kalpathy, Santhosh and Lopez, Alexandra M and Pena, Erik S and Bachelder, Jacob M and Sellers, Rani S and Abraham, Soman N and Staats, Herman F and Ainslie, Kristy M},
  title = {Dual-adjuvant mucosal vaccine leveraging mast cell and TLR9 agonists for protection against poxvirus infection},
  journal = {RSC Pharmaceutics},
  year = {2026},
  volume = {3},
  number = {4},
  pages = {1022--1033},
  doi = {10.1039/d5pm00380f}
}
Kostenlos starten →